×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
How Can Studies that Inform Relative Effectiveness Best Be Incorporated into Global Drug Development Plans?
Session Chair(s)
Chris Chinn, MSc
Real World Evidence for Market Access
Sanofi, United Kingdom
GetReal, an EU Innovative Medicines Initiative (IMI) public-private partnership composed of pharmaceutical companies, academia, health technology assessment (HTA) agencies, and regulators, will host a discussion on ways of incorporating relative effectiveness objectives into pre-authorization development, and the implications for international HTA, regulatory, and drug development decision-making.
Learning Objective : Recognize the regulatory, health technology assessment (HTA), and operational challenges facing the implementation of alternative drug development strategies prior to medicine authorization; Explain how global drug development plans can better incorporate relative effectiveness objectives, real-world data, and analytical techniques prior to medicine authorization.
Speaker(s)
Panelist
Chris Chinn, MSc
Sanofi, United Kingdom
Real World Evidence for Market Access
Panelist
Mark Trusheim, MS, MSc
Tufts Medical Center, United States
Strategic Director, NEWDIGS
Have an account?